Clinical Trial Update: Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients [Phase 3]

View source ↗

Summary

This clinical trial update covers safety and efficacy data from a Phase 3 study of AVP-923 for pseudobulbar affect in patients with multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Pseudobulbar Affect

Drugs mentioned

• AVP-923

Snippet

Sponsor: Avanir Pharmaceuticals | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED